Weekly Analysts’ Ratings Updates for Revvity (RVTY)

Revvity (NYSE: RVTY) recently received a number of ratings updates from brokerages and research firms:

• 10/13/2026 – Revvity had its price target raised by TD Cowen from $130.00 to $175.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Revvity was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 10/7/2026 – Revvity had its price target raised by Barclays PLC from $115.00 to $160.00. They now have an “equal weight” rating on the stock.
• 10/5/2026 – Revvity is now covered by William Blair. They set an “outperform” rating on the stock.
• 9/9/2026 – Revvity is now covered by UBS Group AG. They set a “neutral” rating and a $140.00 price target on the stock.
• 9/4/2026 – Revvity had its price target raised by KeyCorp from $125.00 to $165.00. They now have an “overweight” rating on the stock.
• 9/1/2026 – Revvity is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $135.00 price target on the stock.
• 9/1/2026 – Revvity is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $135.00 price target on the stock.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio is 13.33%.

Insiders Place Their Bets

In other news, insider Tajinder S. Vohra sold 7,330 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider directly owned 6,635 shares of the company’s stock, valued at $934,738.80. This trade represents a 52.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Maxwell Krakowiak sold 1,631 shares of Revvity stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the transaction, the insider owned 14,781 shares in the company, valued at $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 9,130 shares of company stock valued at $1,290,745 in the last quarter. Insiders own 0.85% of the company’s stock.

Revvity, Inc (NYSE:RVTY) is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.

Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.